Clinical trials
Browse topics Search all clinical trials
The purpose of this study is to evaluate whether subcutaneous (SC) administration of the study drug, fitusiran, is effective and safe, in particular in reducing the number of treated bleeding episodes in participants (aged greater than or equal to 12 years) with hemophilia A or B with or without inhibitory antibodies to Factor VIII or IX.
Long Island Jewish Medical Center | 270-05 76th Avenue | New Hyde Park | NY 11040
Long Island Jewish Medical Center | 270-05 76th Avenue | New Hyde Park | NY 11040